Sysmex (SSMXF) Price & Analysis
SSMXF Stock Chart & Stats
- Day’s Range
- $10.79 - $13.35
- 52-Week Range
- $7.76 - $13.80
- Previous Close
- $12.28
- Volume
- 200
- Average Volume (3M)
- 32
- Market Cap
- $7.42B
- Enterprise Value
- $912.23B
- Total Cash (Recent Filing)
- $113.63B
- Total Debt (Recent Filing)
- $123.53B
- Price to Earnings (P/E)
- 30.4
- Beta
- -0.12
- Next Earnings
- Nov 10, 2026
- EPS Estimate
- 0.1
- Next Dividend Ex-Date
- Mar 30, 2027
- Dividend Yield
- 1.99%
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Model
Sysmex combines upfront analyzer sales with recurring, instrument-specific consumables and service revenue. As its installed base expands, routine testing can support repeat purchases and create a durable revenue foundation that is less dependent on one-time equipment placements.
Conservative Balance Sheet
Very low leverage gives Sysmex substantial financial flexibility to fund product development, international expansion, and customer support without relying heavily on debt. A strong equity base also improves resilience if healthcare spending or operating conditions weaken.
Strong Cash Generation
Sysmex is generating meaningful operating and free cash flow, and the strong rebound in FCF increases its capacity to reinvest, maintain its installed base, and return capital. Sustained cash generation supports the business even while profitability metrics are being monitored.
Bears Say
Margin Compression
Falling net and EBIT margins indicate that revenue growth is currently translating into less profit than in prior years. If this persists, weaker operating leverage could limit earnings growth, reduce reinvestment capacity, and make future returns more dependent on top-line expansion.
Declining Earnings Per Share
Negative EPS growth despite positive revenue growth shows that current expansion is not fully reaching shareholders as earnings. This divergence reinforces the concern that cost, profitability, or operating factors are absorbing a meaningful portion of incremental sales.
Moderate Cash Conversion
Although absolute cash generation is healthy, only moderate conversion from EBITDA and net income suggests that working capital, taxes, or capital spending are absorbing part of reported profitability. Persistent conversion pressure could constrain the cash available for growth and capital returns.
Sysmex News
SSMXF FAQ
What was Sysmex’s price range in the past 12 months?
What is Sysmex’s market cap?
When is Sysmex’s upcoming earnings report date?
How were Sysmex’s earnings last quarter?
Is Sysmex overvalued?
Does Sysmex pay dividends?
What is Sysmex’s EPS estimate?
How many shares outstanding does Sysmex have?
What happened to Sysmex’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sysmex?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sysmex
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Hisashi Ietsugu
- Employees
- 10,861
- Website
- www.sysmex.co.jp
- Address
- 1-5-1, Wakinohama-Kaigandori, Kobe, HY, 651-0073, JP
Sysmex (SSMXF) Earnings & Revenues
SSMXF Company Deck
SSMXF Earnings Call
Earnings Call SentimentNegative
The earnings call presented several notable challenges, including a significant revenue decline due to a system transition in Japan and the impact of China's medical cost control policies. However, there were positive developments such as the launch of new products and progress in Alzheimer's testing. Despite these positive aspects, the lowlights indicating declines in revenue and profit suggest a cautious outlook.
View all SSMXF earnings summariesSSMXF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 6 | 6 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 8 | 0 | 4 |








